Abstract
Recent developments in gene therapy have increased the need for the large-scale production of pharmaceutical-grade plasmid DNA. Regulatory agencies require final preparations to be free of host RNA, genomic DNA, proteins and lipopolysaccharides. This paper reports the application of anion-exchange high-performance liquid chromatography (HPLC) to the analysis of process streams during the downstream processing of plasmid DNA for gene therapy. An HPLC purity degree and a purification factor were defined and used to demostrate that process ion-exchange largely reduces the amount of impurities (purification factor of 70.1). However, since plasmid purity after ion-exchange was 59.3% a further gel-filtration step was included in order to reach 100% purity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
